<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657017</url>
  </required_header>
  <id_info>
    <org_study_id>PET/MR-2018-01</org_study_id>
    <nct_id>NCT03657017</nct_id>
  </id_info>
  <brief_title>PET/MR in Locally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>PET/MR in Locally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PET/MR in Locally Advanced Nasopharyngeal Carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multiparametric PET/MRI-based radiomics nomograms for locally advanced nasopharyngeal carcinoma</measure>
    <time_frame>From day 1 of chemotherapy to the date of the event, a minimum follow-up of 3 years.</time_frame>
    <description>Radiomics-based prognostic model by PET/MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction model of the efficiency of treatment in locally advanced nasopharyngeal carcinoma</measure>
    <time_frame>about 4 years (all of patients complete treatment)</time_frame>
    <description>Radiomics-based prediction model of the efficiency of treatment by PET/MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>PET/MR</condition>
  <arm_group>
    <arm_group_label>PET/MR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are examined with PET/MR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET/MR</intervention_name>
    <description>Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.</description>
    <arm_group_label>PET/MR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed non-keratinizing carcinoma.

          -  Tumor staged T1-4N0-3M0 （according to the 8th AJCC staging system）

          -  Performance status: KPS&gt;70

          -  With normal liver function test (ALT, AST &lt;1.5ULN)

          -  Renal: creatinine clearance &gt;60ml/min

          -  Without hematopathy,marrow: WBC &gt;4*109/L, HGB&gt;80G/L, and PLT&gt;100*109/L.

          -  Written informed consent

        Exclusion Criteria:

          -  Adenocarcinoma

          -  Age &gt;70

          -  Prior malignancy (except adequately treated carcinoma in-situ of the cervix or ·
             basal/squamous cell carcinoma of the skin)

          -  Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside
             the intended RT treatment volume)

          -  Patient is pregnant or lactating

          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose
             &gt;1.5×ULN), or emotional disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caineng Cao, MD</last_name>
    <phone>0571-88128202</phone>
    <email>caocaineng777@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiaozhong Chen</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen, MD</last_name>
      <phone>+86-571-88128202</phone>
      <email>cxzfyun@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>August 31, 2018</last_update_submitted>
  <last_update_submitted_qc>August 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Chen Xiaozhong</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

